Ukr.Biochem.J. 2017; Volume 89, Special Issue, pp. 102-110

doi: https://doi.org/10.15407/ubj89.si01.102

Glu- and Lys-forms of plasminogen differentially affect phosphatidylserine exposure on the platelet surface

27.03.2017   Uncategorized   No comments

D. D. Zhernossekov, Y. M. Roka-Moiia, A. O. Tykhomyrov,
M. M. Guzyk, T. V. Grinenko

Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv;
e-mail: chemikdd@mail.ru

Plasminogen/plasmin system is known for its ability to support hemostatic balance of blood. However, plasminogen may be considered as an adhesive ligand and in this way could affect the functioning of blood cells. We showed that exogenous Lys-plasminogen, but not its Glu-form, inhibited platelet aggregation and suppressed platelet α-granule secretion. The aim of this work was to investigate the influence of Glu- and Lys-form of plasminogen on the formation of platelet procoagulant surface using phosphatidylserine exposure as a marker. Human platelets were obtained from human platelet-rich plasma (donors were healthy volunteers, men aged 30-40 years) by gel-filtration on Sepharose 2B. Phosphatidylserine exposure on the platelet surface was evaluated by flow cytometry with FITC-conjugated annexin A5. Glu- and Lys-plasminogen have different impact on the platelet functioning. Exogenous Lys-plasminogen has no significant effect on phosphatidylserine exposure, while Glu-plasminogen increases phosphatidylserine exposure on the surface of thrombin- and collagen-activated human platelets. Glu-plasminogen can be considered as a co-stimulator of agonist-induced platelet secretion and procoagulant surface formation. Meanwhile effects of Lys-plasminogen are probably directed at platelet-platelet interactions and not related to agonist-stimulated pro-apoptotic changes. The observed different effects of Glu- and Lys-plasminogen on phosphatidylserine exposure can be explained by their structural peculiarities.

Keywords: , ,

References:

  1. Lishko VK, Novokhatny VV, Yakubenko VP, Skomorovska-Prokvolit HV, Ugarova TP. Characterization of plasminogen as an adhesive ligand for integrins alphaMbeta2 (Mac-1) and alpha5beta1 (VLA-5). Blood. 2004 Aug 1;104(3):719-26. PubMed, CrossRef
  2. Holvoet P, Lijnen HR, Collen D. A monoclonal antibody specific for Lys-plasminogen. Application to the study of the activation pathways of plasminogen in vivo. J Biol Chem. 1985 Oct 5;260(22):12106-11. PubMed
  3. Miles LA, Castellino FJ, Gong Y. Critical role for conversion of glu-plasminogen to Lys-plasminogen for optimal stimulation of plasminogen activation on cell surfaces. Trends Cardiovasc Med. 2003 Jan;13(1):21-30. Review. PubMed, CrossRef
  4. Miles LA, Dahlberg CM, Plow EF. The cell-binding domains of plasminogen and their function in plasma. J Biol Chem. 1988 Aug 25;263(24):11928-34. PubMed
  5. Tykhomyrov AA, Zhernossekov DD, Roka-Moya YM., Diordieva SI, Grinenko TV. The effects of Lys-plasminogen on human platelet secretion. Fiziol Zh. 2015; 61(6): 26-34. (In Ukranian). PubMed, CrossRef
  6. Roka-Moya YM, Zhernossekov DD, Grinenko TV. Plasminogen/plasmin influence on platelet aggregation. Biopolym Cell. 2012; 28, 5:352-356.  CrossRef
  7. Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science. 1970 Dec 4;170(3962):1095-6. PubMed, CrossRef
  8. Kruger LA, Barnard MR, Frelinger AL III., Furman ML, Michelson AD. Immunophenotypic analysis of platelets. Current protocols in cytometry. New York, John Wiley and Sons; 2002.
  9. Zhernossekov DD, Roka-Moiia YM, Grinenko TV. Extracellular annexins in hemostasis system. Biopolym Cell. 2016; 32(2):98-104. CrossRef
  10. Whyte CS, Swieringa F, Mastenbroek TG, Lionikiene AS, Lancé MD, van der Meijden PE, Heemskerk JW, Mutch NJ. Plasminogen associates with phosphatidylserine-exposing platelets and contributes to thrombus lysis under flow. Blood. 2015 Apr 16;125(16):2568-78. PubMed, PubMedCentral, CrossRef
  11. Das R, Plow EF. Phosphatidylserine as an anchor for plasminogen and its plasminogen receptor, histone H2B, to the macrophage surface. J Thromb Haemost. 2011 Feb;9(2):339-49. PubMed, PubMedCentral, CrossRef
  12. O’Mullane MJ, Baker MS. Elevated plasminogen receptor expression occurs as a degradative phase event in cellular apoptosis. Immunol Cell Biol. 1999 Jun;77(3):249-55. PubMed, CrossRef
  13. Dörmann D, Clemetson KJ, Kehrel BE. The GPIb thrombin-binding site is essential for thrombin-induced platelet procoagulant activity. Blood. 2000 Oct 1;96(7):2469-78. PubMed
  14.  Kakkar VV, Scully MF. Intermittent plasminogen-streptokinase treatment of deep vein thrombosis. Haemostasis. 1988;18 Suppl 1:127-38. PubMed, CrossRef
  15. Shen Y, Guo Y, Mikus P, Sulniute R, Wilczynska M, Ny T, Li J. Plasminogen is a key proinflammatory regulator that accelerates the healing of acute and diabetic wounds. Blood. 2012 Jun 14;119(24):5879-87. PubMed, CrossRef
  16. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care. 2001 Aug;24(8):1476-85. Review. PubMed, CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.